McCall’s “World’s First $1 Million Stock” Teaser… Answered

What's being teased by NexGen Investor as the "Amazon of Biotech?"

By Travis Johnson, Stock Gumshoe, March 13, 2018

Matt McCall is pitching a “$200 into $1 million” stock idea as he tries to drum up subsribers for his NexGen Investor… and that sounds fun, right, owning a stock that goes to a million dollars per share?

It probably won’t happen, of course, and I don’t know how many times it might have actually happened in history — even the stocks that you’d think could be close to that level don’t generally have returns that remarkable, and most have split their shares a bunch of times in the interim to make them more palatable for new investors to consider (Amazon, for example, would be at roughly $15,000 per share right now if it weren’t for stock splits — a nice gain from the $18 IPO price, but even that’s not in the “$200 into $1 million” category… Amazon IPO investors who held on for 20+ years to today would have turned $200 into about $165,000).

But anyway, McCall’s “passion,” he says is to bring you the next great early-stage disruptor that could make investors rich… he uses the examples that make us all feel greedy, like Netflix, Amazon, Tesla, Apple and Facebook, and then leads into his spiel about this new stock:

“It features another early-stage profit opportunity that could be bigger than ALL of these past moneymakers….

“I realize this sounds hard to believe.

“But not when you realize this company possesses a game-changing DNA technology that’s about to turn the $3.3 trillion health care industry upside down.

“That’s not just me saying this.

“Bloomberg says this technology ‘will change the world.’

“Forbes calls it ‘the next step in human evolution.’

“Nobel Prize-winning scientist David Baltimore agrees that this DNA breakthrough will usher in ‘a new era in human history.'”

Those are references to the CRISPR-Cas9 gene editing discoveries and advancements that we’ve seen over the past few years, though there’s seemingly been as much action in the patent courts as in the clinic. The Bloomberg reference is from this article about the patent fight between Feng Zhang and the other early CRISPR researchers Jennifer Doudna and Emmanuelle Charpentier, the Forbes quote is likely from this article, and the quote from David Baltimore has been widely circulated in stories about gene editing, it’s from his opening remarks to the International Summit on Human Gene Editing in December 2015.

And there’s plenty more of this general boosterism for genetic editing:

“… this DNA technology allows researchers, on the cellular level, to ‘cut out’ the bad strands of DNA that are the root cause of hundreds of chronic diseases.

“I call it Genesis because it has the power to virtually rebuild every DNA from the beginning.”

As well as some references to specific “cures” or treatments that have caught peoples’ attention — like the story of Christian Guardino, who regained his sight thanks to gene therapy (using what is now called Luxturna, from Spark Therapeutics — which is certainly a gene therapy, and it was huge news when they got approval in December, though it’s not a therapy that relies on CRISPR-Cas9 editing technology).

So all of that, and most of the big picture stuff he cites in the ad, is about the promise of gene editing and genetic therapies in general… and mostly about the rapid speed of advancement in that field thanks to the precise tool that CRISPR-Cas9 editing gives researchers. We can agree on that basic “genetic editing is a big deal” premise, though I have no idea when it will become something that we can rationally analyze when it comes to economics… partly because much of this is still lab science that has barely begun human testing, and partly because the economics are completely untested and will shake up the pharmaceutical business — how much is a “one shot cure” worth? Who pays? There was an interesting Wired article on this following the JP Morgan Healthcare Conference a couple months ago, should you want to dig deeper.

But anyway, let’s move on to see what other specifics we get — OK? See if we can name this “secret” company that McCall says will be the “world’s first $1 million stock” for you?

First, we’ll sift through and see if there are any more clues… he continues to use these terms and seems to mix the ideas and technologies pretty interchangeably, referring to the whole broad spectrum of CRISPR and gene editing and gene therapies as “Genesis DNA editing” … and then we get some more specific hints:

“… this is no longer experimental technology. It’s proven and far beyond the discovery phase. Our top pick in this sector already has two gene-editing products on the market, two more nearing commercialization, and four more programs in clinics—giving it one of the greatest pipelines of DNA cures in the industry.”

OK, so it’s definitely not one of the “big three” CRISPR stocks — Editas (EDIT), Crispr Technologies (CRSP) and Intellia Therapeutics (NTLA) are the leading names in the public CRISPR space (and the CRISPR patent fights), but none of them have “products on the market” or near commercialization, nor do they have clinical programs. These are R&D companies that are just barely beginning to consider human testing.

So who is it? More clues:

“We’ve already seen the stock’s price jump 342% since March 2016. With two more life-saving DNA products near commercialization, we expect the company’s stock to jump another 342% over the next two years.

“That’s just the beginning…

“The big money will be made as their treatments become as common as Band-Aids over the next 30 years….

…add just one share of this $200-a-share company to your holdings now”

And thankfully, we get a little chart of the company’s progress since early 2016 — when it has gained 342.35% versus the S&P 500’s 45.03%, so that level of specificity makes the Thinkolator happier, and lets us confirm that yes, this “world’s first $1 million stock” teaser is all about bluebird bio (BLUE).

Which is indeed pretty close to $200 a share, it’s at about $225 right now after a 10% jump in the past couple weeks. They reported their fourth quarter earnings about three weeks ago, you can see some summary notes on that from the Motley Fool here. The company is using combinations of gene therapy, gene editing and immunotherapy to develop treatments for cancers and rare diseases, including ALD and sickle cell disease, but probably their most-followed drug is bb2121, which is partnered with Celgene for multiple myeloma.

Will bluebird be a huge winner from here? You’d have to be a damn site smarter than me to prognosticate what their financials might look like in ten years, if and when they have a portfolio of revenue-generating therapies generating lots of cash, so right now it’s all about what value is placed on innovation and how much big pharma partners might want to pay for access to bluebird’s technology or pipeline — it’s already an $11 billion company, so if they’re going to turn $200 into $1 million over the next 30 years, assuming no share buybacks or share sales, then bluebird would be a $55 trillion company in 2048. I suppose that’s possible, but it’s definitely not in the “probable” category in my book — I wouldn’t plan my retirement savings around that expectation.

Which doesn’t mean it’s a bad stock, of course, or that it might not work out fine — it’s just a reminder that you have to ignore the ridiculous promises of teaser ads before you can step back and consider the stocks they recommend with some level of rational thought. I won’t go further into looking at bluebird here, plenty of you have invested in it or commented on the stock in the past and we’ve covered it pretty recently, when Charles Mizrahi was pitching it for his Park Avenue Investment Club back in January as the “biggest breakthrough since chemo.”

And what about McCall and that “NexGen Investor” service? That’s fairly new and we don’t know much about it — his claimed returns are pretty remarkable, per the ad:

“Since he launched NexGen Investor in May of 2017, his picks have handed his readers average annualized gains of 1,011%.”

Which indicates to me that he has probably included a bunch of short-term windfall gains, like successful options trades, or perhaps some cryptocurrency trades that had remarkable jumps (he did tease some crypto-related stocks for one of his other NexGen newsletters back in December). If you post a 20% gain in a particular week for a short-term position, for example, that’s an “annualized gain” of 1,040%, even though, of course, you’re not likely to get that kind of trading gain each week unless you have an extraordinary run of luck.

(My most successful short-term trade over the past year, for example, was a lucky speculation on Nasdaq ETF (QQQ) call options that posted a four month return of 2,250% or so, which would be an annualized return of 6,750%. That’s obviously nice, and I suppose I could claim an annualized gain of 1,000% even if I posted 100% losses on a handful of similar speculations, but be careful about the term “annualized” when people use it to talk about huge recent gains — it’s more useful when you’re talking about long-term performance, and, of course, actual gains are much more important than ‘annualized’ gains.)

So if you have tried out McCall’s products in the past, or subscribed to his NexGen Investor, we don’t yet have any subscriber feedback on that publication, so please do click here and let your fellow readers know what you thought.

And, as always, we learn from each other… if you’ve a thought or opinion to share on bluebird bio, or on the financial dreams inspired by any of the gene editing or gene therapy stocks, CRISPR or otherwise, feel free to share them with a comment below.


Are you getting our free Daily Update "reveal" emails?
If not, just click here...



Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)

Share your thoughts...

23 Comments on "McCall’s “World’s First $1 Million Stock” Teaser… Answered"

Notify of
avatar

This site uses Akismet to reduce spam. Learn how your comment data is processed.

yukonjack
Guest
0
The druggies will fight this tooth and nail. If it becomes possible to cut out bad DNA, which I seriously doubt, then drugs will become extinct. Big Pharma wants to keep us sick for decades so that instead of curing us, they can medicate us to death, slowly. A $million stock in the making? It has never come close to happening and never will until perhaps the Dow trades at 500,000 or some such. Still waiting for the “God Key” to provide 50,000% returns. Check back in about 20 years on all these “miracle” promises.
Add a Topic
5971
Add a Topic
4194
Dave S.
Guest
0

Messing with DNA will not cure all diseases. Many diseases may have a genetic component, but are also strongly influenced by environmental/behavioral factors. No matter how sophisticated DNA manipulation becomes, drugs will be with us for a long time. And no, the pharma companies are not trying to keep us sick.

Britt
Guest
0

Motley Fool has been touting BLUE for a while. They’ve also been touting Celgene (CELG) which hasn’t done a whole lot since its big fall back in October. BLUE’s been doing better, though they did lose over 4% today, but I’m wondering if it isn’t time to put money in CELG.

Add a Topic
329
Add a Topic
4286
archegos2691
Irregular
28

Play it safe here…buy ARKG ETF …it has all these hot biotech stocks.

Add a Topic
900
brenton
Guest
0
There are a lot of rare/orphan diseases that no big pharma companies will touch that could be impacted by CRISPR technologies. But picking a winner amongst the leading companies is going to be difficult and there’s the possibility that others enter the market too. There is a lot of work going on to build a better CRISPR enzyme and if this new enzyme is better (and patented) it could take over rapidly. There were a couple great papers a week or 2 ago that detailed a new enzyme with better specificity, less off-target cuts etc that shows how quickly this… Read more »
Add a Topic
5254
Add a Topic
5254
dcinvest
Irregular
35
Travis, your common sense approach is worth a 1,000 % imaginary gains on that perfect get rich stock. Recently a long time promoter that works for a company on the Vancouver exchange where I have lost thousands in prior years finally hit it big. Over 2-3 years he kept promoting a nickel stock when it was at 3 – 5 cents per share and as of last September it went to 11 cents per share. Well, I didn’t buy because I had no proof their nickel search exploration would ever cause the stock to go up. Wrong. It is now… Read more »
Add a Topic
5971
Add a Topic
964
Add a Topic
5971
michael lacy
Guest
0
Travis, as a beginning investor who is only trying to keep my head above water with astronic medical bills due to an unseen spinal cord injury you have no idea how much I appreciate your common sense no nonsense straight to the analytical point. I can’t afford to fall into stock advice from so many “stock advice for sale promoters” who could care less if I lose what miniscule amount of money I do have. To me Travis, you’re the last ethical man who helps so many, not for money, but because you care. Put a price on a sincere… Read more »
Add a Topic
540
Add a Topic
5971
Add a Topic
5971
Gr8Full!
Irregular
11282

Mike, that is the nicest, most eloquently stated, true comment in existence, regarding Travis, Please except my small gift of one year Irregular membership to StockGumshoe; the only subscription an investor needs for a fighting chance against these effed up markets full of wolves and scammers. Lynn, please send me an invoice.
Long #Gr8Gummunity, sharing and caring. #Best2YouAlwayz – Ben

StockMidas
Irregular
236

Great gesture Ben !!
I reiterate once again my sentiments about the stock market pundits which can be summed up in two words – Be Aware:
https://www.stockgumshoe.com/2017/12/microblog-guru-ish-pundits-2/

Add a Topic
5971
Gr8Full!
Irregular
11282

#Laa0709,, Had previously missed your thread. Subscribed. Well done Chief!

tanglewood
Irregular
347

Ben, you are at the top of the class in the Gr8Gummunity. Thank you for doing that, at 4:30 in the morning no less, and for all you do for us.

Timothy Hudnut
Guest
0

Ben: You are a true humanitarian to make a kind gesture to Mike regarding the eloquent statement about Travis’s ground work. I am a new reader in the last two weeks and find Travis’s research extremely worthy at this time. I am in the same shoes as Michael is, with a terrible back surgery gone wrong. There are so many awful advertisements out there tease you out of curiosity that it is confusing to really be convinced where to go for great advice for investment purposes.

Add a Topic
6225
StockMidas
Irregular
236

Mike, send me a message to trader709@yahoo,.com

StockMidas
Irregular
236

Apologies – was duplication. Cannot delete this.

Upendra
Guest
0
Mike, totally agree with you. I hope you do recover soon and are able to resolve your situation. Your assessment of Travis is spot on!. I too am a novice investor and always looking for ways to support my family, not easy when you’re unemployed. I am not seeking any freebies, but I always refer to comments here to various trading services I receive via Email. We are bombarded with so much hype about making money through various services, yet none are for sure. From my assessment, I haven’t seen anything reliable from these so-called experts whos has been trading… Read more »
johnnyboy
Guest
0
KO in the veins; then another industrial mass production to have undo it obviously. The theory is sound as coke is “bad for one” and “we’re all addicts.” This teaser “is doomed to pay big.” Reminds me of when Buffy eats too much Dairy Q. ice cream, gets rabid, shorts everything in his account -he’s too rabid to care he now gets 0 divs until he gets over his fit and covers- viola 2008. Side benefit is stocks are awfully cheap then. Well, really tho – MASS[ive] PRODUCTION. The keys to the world’s wallet out there. ‘t’s why, when the… Read more »
Add a Topic
372
Add a Topic
4194
Add a Topic
5242
johnnyboy
Guest
0

Edit: (No way to edit original!):
Should have included as:

“This teaser, (BLUE), “is doomed to pay big.”

Or it’s like “What’s this nut talking about?” for the rest of it.

Need edit capability in Gumshoe comments.

Add a Topic
372
johnnyboy
Guest
0

This is an ultimatum. We either get edit capabilities of our original post or people are going to find out I AM some kind of one (nut) as I spew out my spontaneous first thought. With edit capabilities we will be able to decorously hide something like that better.

Cookie P
Guest
0

Please note that genetics are such a small percentage of a person’s actual health outlook that”editing” genes will accomplish little except in rare or extreme cases. Habits, environment, attitude and behavior, which only oneself can “edit, are what works. No silver bullet.

Add a Topic
443
Rodney
Guest
0
Man seeing they guy pay for the other mans subscription was really cool. Fwiw I enjoy the comments just as much as the articles here and have found some really great stocks from some of you. I don’t come here often enough but after reading this thread I am going to change that & hopefully get a better handle for the guys here that are regular commenters etc. This is my second comment ever here and the first one was asking if the gentleman commenting in the weed stock thread the other day was Rainman. It’s was hard for me… Read more »
Add a Topic
372
Add a Topic
5971
Gr8Full!
Irregular
11282
macaries
Member
11

BLUE is falling like a rock There is no profit in their near future look at the losses per quarter or annually. 9billion valuation right now Might be an options play now

Add a Topic
570
wpDiscuz